The briefing
Researchers reported that key antiviral proteins did not effectively counter SARS-CoV-2 in some severe COVID-19 patients, linking the issue to a diverse population of B cells. The findings may help explain outcome differences and guide future therapeutic strategies.
Original headline
Study reveals why key antiviral defenses failed in some severe COVID-19 patients